Safety and efficacy of COVID-19 hyperimmune globulin (HIG) solution in the treatment of active COVID-19 infection- Findings from a Prospective, Randomized, Controlled, Multi-Centric Trial

Devang Parikh, Alok Chaturvedi, Naman Shah, Piyush Patel, Ronak Patel, Suma Ray
doi: https://doi.org/10.1101/2021.07.26.21261119

Article Information

doi 
https://doi.org/10.1101/2021.07.26.21261119
History 
  • July 27, 2021.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

Author Information

  1. Devang Parikh, Senior Manager1,
  2. Alok Chaturvedi, Senior Vice President2,
  3. Naman Shah, Senior General Manager3,
  4. Piyush Patel, Assistant General Manager2,
  5. Ronak Patel, Associate Vice President5 and
  6. Suma Ray, Senior Vice President6,*
  1. 1Clinical Development & Medical Affairs, Intas Pharmaceuticals Ltd
  2. 2Medical Affairs, Intas Pharmaceuticals Ltd
  3. 3Medical Services, Lambda Therapeutics Research Ltd
  4. 5Biostatistics & Programming. Lambda Therapeutics Research Ltd
  5. 6Plasma Operations, Intas Pharmaceuticals Ltd
  1. ↵*Corresponding address Dr. Suma Ray
    , Senior Vice President, Plasma Operations, Intas Pharmaceuticals Ltd., Plot no. 496/1/A&B, Sarkhej-Bawla Highway, Matoda, Sanand, Ahmedabad-382213, Gujarat, India., Tel. No.: +91-2717-662157, Email: Suma_ray{at}intaspharma.com
Back to top
Posted July 27, 2021.
Download PDF

Supplementary Material

Data/Code
Email
Safety and efficacy of COVID-19 hyperimmune globulin (HIG) solution in the treatment of active COVID-19 infection- Findings from a Prospective, Randomized, Controlled, Multi-Centric Trial
Devang Parikh, Alok Chaturvedi, Naman Shah, Piyush Patel, Ronak Patel, Suma Ray
medRxiv 2021.07.26.21261119; doi: https://doi.org/10.1101/2021.07.26.21261119
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area